Get the Stockscreener App
1.26
11.27%
-0.16
NanoViricides Inc Stock (NNVC) Latest News
Small cap headlines: EnWave, NanoViricides, GoviEx, TNR Gold... - Proactive Investors UK
NanoViricides targets key milestones in 2025 with NV-387 advancing to Phase II trials - Proactive Investors UK
NanoViricides, Inc. Has Filed its Quarterly Report - Oil City Derrick
NanoViricides, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2024 - Marketscreener.com
NanoViricides Inc. (NNVC) reports earnings - Quartz
NanoViricides: Fiscal Q2 Earnings Snapshot - San Antonio Express-News
NanoViricides: Fiscal Q2 Earnings Snapshot -February 14, 2025 at 04:38 pm EST - Marketscreener.com
Is NanoViricides Inc. (NNVC) the Best Nanotech Penny Stock to Invest In? - Insider Monkey
7 Best Nanotech Penny Stocks to Invest In - Insider Monkey
NanoViricides announces readiness to combat bird flu with antiviral drug NV-387 - Proactive Investors UK
NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape - Oil City Derrick
Powerful New Weapon Against Bird Flu: NanoViricides' Drug Outperforms Tamiflu in Lab Tests - StockTitan
NanoViricides Provides an Update on Its Clinical Program and StrategyNV-387 Could be As Revolutionary as Antibiotics - ACCESS Newswire
NanoViricides seeks to eliminate treatment delays with its broad spectrum antiviral NV-387 - Proactive Investors UK
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
NNVC’s price-to-cash ratio: Is it a good investment at the moment? - US Post News
NanoViricides warns of bird flu pandemic as outbreak spreads in Massachusetts - Proactive Investors USA
NanoViricides (NYSE:NNVC) Trading Down 1.8% – What’s Next? - Defense World
NanoViricides to present at MicroCap Conference 2025 in Atlantic City - Proactive Investors Australia
Game-Changing Antiviral Drug Shows 'Superior Results' Against Multiple Viruses$10B Market Potential - StockTitan
NanoViricides advances antiviral drug with Phase II Clinical trial to Combat MPox - Proactive Investors USA
NanoViricides taps clinical research organization for Phase II trial of NV-387 - Proactive Investors UK
NanoViricides Engages CRO for Phase II Clinical Trial - Oil City Derrick
NanoViricides to Present at the Biotech Showcase in San Fransisco - ACCESS Newswire
Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals - ACCESS Newswire
NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025 - ACCESS Newswire
NanoViricides to present antiviral drug pipeline at Biotech Showcase 2025 - Proactive Investors Australia
NanoViricides CEO discusses NV-387’s broad spectrum promiseICYMI - Proactive Investors Australia
NanoViricides highlights urgent need for broad-spectrum antiviral solutions amid viral threats - Proactive Investors Australia
NanoViricides (NYSE:NNVC) Trading Down 5% – Should You Sell? - Defense World
First US bird flu fatality raises alarms over mutations in H5N1 virus - Proactive Investors USA
NanoViricides CEO discusses groundbreaking broad-spectrum antiviral treatment - Proactive Investors UK
NanoViricides, Inc. Files Quarterly ReportReports a Strong Cash Position Sufficient for Initial C - AOL
NanoViricides sees NV-387 as a key defense against bird flu pandemic - Proactive Investors UK
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape - Oil City Derrick
NanoViricides' NV-387 Shows Breakthrough 88% Survival Rate Against H5N1 Bird Flu in Key Study - StockTitan
NanoViricides CEO highlights urgency of H5N1 preparedness as cases rise in North America By Proactive Investors - Investing.com UK
NanoViricides CEO highlights urgency of H5N1 preparedness as cases rise in North America - Proactive Investors UK
NanoViricides: Pioneering the Future of Antiviral Therapies - TechBullion
NanoViricides (AMEX:$NNVC) Leads Innovation In Broad-Spectrum Antiviral Therapies - Barchart
NanoViricides (AMEX:$NNVC) Leads Innovation in Broad-Spectrum Antiviral Therapies - openPR
NanoViricides (NYSE:NNVC) Rating Lowered to “Sell” at StockNews.com - Defense World
NanoViricides pushes NV-387 to Phase II trials - Proactive Investors Australia
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):